Literature DB >> 14685937

Variation in a repeat sequence determines whether a common variant of the cystic fibrosis transmembrane conductance regulator gene is pathogenic or benign.

Joshua D Groman1, Timothy W Hefferon, Teresa Casals, Lluís Bassas, Xavier Estivill, Marie Des Georges, Caroline Guittard, Monika Koudova, M Daniele Fallin, Krisztina Nemeth, Gyorgy Fekete, Ludovit Kadasi, Ken Friedman, Martin Schwarz, Cristina Bombieri, Pier Franco Pignatti, Emmanuel Kanavakis, Maria Tzetis, Marianne Schwartz, Giuseppe Novelli, Maria Rosaria D'Apice, Agnieszka Sobczynska-Tomaszewska, Jerzy Bal, Manfred Stuhrmann, Milan Macek, Mireille Claustres, Garry R Cutting.   

Abstract

An abbreviated tract of five thymidines (5T) in intron 8 of the cystic fibrosis transmembrane conductance regulator (CFTR) gene is found in approximately 10% of individuals in the general population. When found in trans with a severe CFTR mutation, 5T can result in male infertility, nonclassic cystic fibrosis, or a normal phenotype. To test whether the number of TG repeats adjacent to 5T influences disease penetrance, we determined TG repeat number in 98 patients with male infertility due to congenital absence of the vas deferens, 9 patients with nonclassic CF, and 27 unaffected individuals (fertile men). Each of the individuals in this study had a severe CFTR mutation on one CFTR gene and 5T on the other. Of the unaffected individuals, 78% (21 of 27) had 5T adjacent to 11 TG repeats, compared with 9% (10 of 107) of affected individuals. Conversely, 91% (97 of 107) of affected individuals had 12 or 13 TG repeats, versus only 22% (6 of 27) of unaffected individuals (P<.00001). Those individuals with 5T adjacent to either 12 or 13 TG repeats were substantially more likely to exhibit an abnormal phenotype than those with 5T adjacent to 11 TG repeats (odds ratio 34.0, 95% CI 11.1-103.7, P<.00001). Thus, determination of TG repeat number will allow for more accurate prediction of benign versus pathogenic 5T alleles.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14685937      PMCID: PMC1181905          DOI: 10.1086/381001

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  10 in total

Review 1.  The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel.

Authors:  B J Rosenstein; G R Cutting
Journal:  J Pediatr       Date:  1998-04       Impact factor: 4.406

2.  CFTR gene variant for patients with congenital absence of vas deferens.

Authors:  J Zielenski; P Patrizio; M Corey; B Handelin; D Markiewicz; R Asch; L C Tsui
Journal:  Am J Hum Genet       Date:  1995-10       Impact factor: 11.025

3.  Polyvariant mutant cystic fibrosis transmembrane conductance regulator genes. The polymorphic (Tg)m locus explains the partial penetrance of the T5 polymorphism as a disease mutation.

Authors:  H Cuppens; W Lin; M Jaspers; B Costes; H Teng; A Vankeerberghen; M Jorissen; G Droogmans; I Reynaert; M Goossens; B Nilius; J J Cassiman
Journal:  J Clin Invest       Date:  1998-01-15       Impact factor: 14.808

4.  Lung disease associated with the IVS8 5T allele of the CFTR gene.

Authors:  P G Noone; C A Pue; Z Zhou; K J Friedman; E L Wakeling; M Ganeshananthan; R H Simon; L M Silverman; M R Knowles
Journal:  Am J Respir Crit Care Med       Date:  2000-11       Impact factor: 21.405

5.  Genetic basis of variable exon 9 skipping in cystic fibrosis transmembrane conductance regulator mRNA.

Authors:  C S Chu; B C Trapnell; S Curristin; G R Cutting; R G Crystal
Journal:  Nat Genet       Date:  1993-02       Impact factor: 38.330

6.  A variable dinucleotide repeat in the CFTR gene contributes to phenotype diversity by forming RNA secondary structures that alter splicing.

Authors:  Timothy W Hefferon; Joshua D Groman; Catherine E Yurk; Garry R Cutting
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-01       Impact factor: 11.205

7.  Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens.

Authors:  M Chillón; T Casals; B Mercier; L Bassas; W Lissens; S Silber; M C Romey; J Ruiz-Romero; C Verlingue; M Claustres
Journal:  N Engl J Med       Date:  1995-06-01       Impact factor: 91.245

8.  Linkage disequilibrium between the M470V variant and the IVS8 polyT alleles of the CFTR gene in CBAVD.

Authors:  A de Meeus; C Guittard; M Desgeorges; S Carles; J Demaille; M Claustres
Journal:  J Med Genet       Date:  1998-07       Impact factor: 6.318

9.  Functional analysis of cis-acting elements regulating the alternative splicing of human CFTR exon 9.

Authors:  M Niksic; M Romano; E Buratti; F Pagani; F E Baralle
Journal:  Hum Mol Genet       Date:  1999-12       Impact factor: 6.150

10.  Cystic fibrosis screening using the College panel: platform comparison and lessons learned from the first 20,000 samples.

Authors:  Charles M Strom; Donghui Huang; Arlene Buller; Joy Redman; Beryl Crossley; Ben Anderson; Tom Entwistle; Weimin Sun
Journal:  Genet Med       Date:  2002 Jul-Aug       Impact factor: 8.822

  10 in total
  60 in total

1.  Long-range (17.7 kb) allele-specific polymerase chain reaction method for direct haplotyping of R117H and IVS-8 mutations of the cystic fibrosis transmembrane regulator gene.

Authors:  Genevieve Pont-Kingdon; Mohamed Jama; Christine Miller; Alison Millson; Elaine Lyon
Journal:  J Mol Diagn       Date:  2004-08       Impact factor: 5.568

2.  Microsphere bead arrays and sequence validation of 5/7/9T genotypes for multiplex screening of cystic fibrosis polymorphisms.

Authors:  Andrew G Hadd; Walairat Laosinchai-Wolf; Chris R Novak; Marty R Badgett; Lesley A Isgur; Marianna Goldrick; Cindy R Walkerpeach
Journal:  J Mol Diagn       Date:  2004-11       Impact factor: 5.568

Review 3.  Cystic fibrosis modifier genes.

Authors:  Jane Davies; Eric Alton; Uta Griesenbach
Journal:  J R Soc Med       Date:  2005       Impact factor: 5.344

4.  CFTR transcription defects in pancreatic sufficient cystic fibrosis patients with only one mutation in the coding region of CFTR.

Authors:  Molly B Sheridan; Timothy W Hefferon; Nulang Wang; Christian Merlo; Carlos Milla; Drucy Borowitz; Eric D Green; Peter J Mogayzel; Garry R Cutting
Journal:  J Med Genet       Date:  2010-11-20       Impact factor: 6.318

5.  Best practice guidelines for molecular genetic diagnosis of cystic fibrosis and CFTR-related disorders--updated European recommendations.

Authors:  Els Dequeker; Manfred Stuhrmann; Michael A Morris; Teresa Casals; Carlo Castellani; Mireille Claustres; Harry Cuppens; Marie des Georges; Claude Ferec; Milan Macek; Pier-Franco Pignatti; Hans Scheffer; Marianne Schwartz; Michal Witt; Martin Schwarz; Emmanuelle Girodon
Journal:  Eur J Hum Genet       Date:  2008-08-06       Impact factor: 4.246

6.  Molecular testing for cystic fibrosis carrier status practice guidelines: recommendations of the National Society of Genetic Counselors.

Authors:  Elinor Langfelder-Schwind; Barbara Karczeski; Michelle N Strecker; Joy Redman; Elaine A Sugarman; Christina Zaleski; Trisha Brown; Steven Keiles; Amy Powers; Sumheda Ghate; Rebecca Darrah
Journal:  J Genet Couns       Date:  2013-09-07       Impact factor: 2.537

7.  Cystic Fibrosis Foundation practice guidelines for the management of infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome during the first two years of life and beyond.

Authors:  Drucy Borowitz; Richard B Parad; Jack K Sharp; Kathryn A Sabadosa; Karen A Robinson; Michael J Rock; Philip M Farrell; Marci K Sontag; Margaret Rosenfeld; Stephanie D Davis; Bruce C Marshall; Frank J Accurso
Journal:  J Pediatr       Date:  2009-12       Impact factor: 4.406

Review 8.  Congenital bilateral absence of the vas deferens as an atypical form of cystic fibrosis: reproductive implications and genetic counseling.

Authors:  D A S de Souza; F R Faucz; L Pereira-Ferrari; V S Sotomaior; S Raskin
Journal:  Andrology       Date:  2017-12-07       Impact factor: 3.842

Review 9.  Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice.

Authors:  C Castellani; H Cuppens; M Macek; J J Cassiman; E Kerem; P Durie; E Tullis; B M Assael; C Bombieri; A Brown; T Casals; M Claustres; G R Cutting; E Dequeker; J Dodge; I Doull; P Farrell; C Ferec; E Girodon; M Johannesson; B Kerem; M Knowles; A Munck; P F Pignatti; D Radojkovic; P Rizzotti; M Schwarz; M Stuhrmann; M Tzetis; J Zielenski; J S Elborn
Journal:  J Cyst Fibros       Date:  2008-05       Impact factor: 5.482

10.  The CFTR polymorphisms poly-T, TG-repeats and M470V in Chinese males with congenital bilateral absence of the vas deferens.

Authors:  Wu-Hua Ni; Lei Jiang; Qian-Jin Fei; Jian-Yuan Jin; Xu Yang; Xue-Feng Huang
Journal:  Asian J Androl       Date:  2012-07-30       Impact factor: 3.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.